MRGPRX2


Escient Presentations

Key Publications

Structure, Function and Pharmacology of Human Itch GPCRs

Cao. et al. Nature, 600:170–175, November 2021.

MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria

Shtessel. et al. Journal of Investigative Dermatology, 141:678-681, March 2021.

House Dust Mites Activate Nociceptor–mast Cell Clusters to Drive Type 2 Skin Inflammation

Serhan. et al. Nature Immunology, 20:1435–1443, October 2019.

A Mast-Cell-Specific Receptor Mediates Neurogenic Inflammation and Pain

Green. et al. Neuron, 101:412–420.e3, February 2019.

The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch

Nattkemper. et al. Journal of Investigative Dermatology, 138:1311 -1317, June 2018.

Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous Urticaria

Metz. et al. Journal of Investigative Dermatology, 134:2833–2836, November 2014.

Expression of Mas-related Gene X2 on Mast Cells is Upregulated in the Skin of Patients with Severe Chronic Urticaria

Fujisawa. et al. Journal of Allergy and Clinical Immunology, 134:622-633.E9, September 2014.


MRGPRX4


Escient Presentations

Pharmacokinetic Modeling of EP547 and Simulations of Exposure in Hepatic Impairment 

ASCPT 2022
Brooks J, Kim T, Chang C, Bentley D. Pharmacokinetic Modeling of EP547 and Simulations of Exposure in Hepatic Impairment. Clin. Pharmacol. Ther. 2022;111(S1):S10. Abstract P-019

Rationale for MRGPRX4 Antagonism as a Treatment for Cholestatic and Uremic Pruritus

AASLD: The Liver Meeting, November 2021
MRGPRX4 Antagonism as a Treatment for Cholestatic and Uremic Pruritis. Hepatology. 2021;74(S1):779A-780A. Abstract 1297.

Development of EP547: A Potent, Highly Selective MRGPRX4 Inverse Agonist for the Treatment of Cholestatic and Uremic Pruritus

AASLD: The Liver Meeting, November 2021
Taylor K, Brooks B, Hemming J, Malloy J, Ferguson B, Baron A, Roberts S, Gane E. First-in-Human Study of EP547, a Potent and Highly Selective MRGPRX4 Inverse Agonist in Development for Treatment of Cholestatic Pruritus. Hepatology. 2021;74(S1):764A-765A. Abstract 1272.

First-in-Human Study of EP547, a Potent and Highly Selective MRGPRX4 Inverse Agonist in Development for Treatment of Cholestatic Pruritus

AASLD: The Liver Meeting, November 2021
Yeager A, Selfridge B, Sainz M, Huang L, Dvorak L, Pisacane C, Solomon M, Pittner R, Timony G, Martinborough E, Boehm M. Development of EP547: A Potent, Highly Selective MRGPRX4 Inverse Agonist for the Treatment of Cholestatic and Uremic Pruritis. Hepatology. 2021;74(S1):757A. Abstract 1262.

Key Publications

MRGPRX4 is a Bile Acid Receptor for Human Cholestatic Itch

Yu. et al. eLife 2019;8:e48431, September 2019.

Cholestatic Itch Management

Mittal, A. Curr Probl Dermatol, 50:142-8, 2016.